<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00928655</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1522A#1-4</org_study_id>
    <nct_id>NCT00928655</nct_id>
  </id_info>
  <brief_title>Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude</brief_title>
  <official_title>Continuous Positive Airway Pressure (CPAP) and Acetazolamide for Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the effect of nasal continuous positive airway
      pressure in combination with acetazolamide as a treatment for sleep related breathing
      disturbances in patients with the obstructive sleep apnea syndrome living at low altitude
      during a sojourn at moderate altitude.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sleep disordered breathing and oxygenation</measure>
    <time_frame>day 2 and 3 at altitude</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sleep quality, vigilance, acute mountain sickness, blood pressure</measure>
    <time_frame>day 2 and 3 at altitude</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Obstructive Sleep Apnea Syndrome</condition>
  <arm_group>
    <arm_group_label>acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination of acetazolamide and nocturnal continuous positive airway pressure ventilation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>combination of placebo and nocturnal continuous positive airway pressure ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetazolamide</intervention_name>
    <description>acetazolamide 250mg 1/0/2</description>
    <arm_group_label>acetazolamide</arm_group_label>
    <other_name>Diamox (trade name)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nocturnal continuous positive airway pressure</intervention_name>
    <description>continuous positive airway pressure</description>
    <arm_group_label>acetazolamide</arm_group_label>
    <arm_group_label>placebo capsules</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>placebo capsules</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obstructive sleep apnea syndrome, successfully on CPAP therapy

          -  Residence at low altitude (&lt; 800 m)

          -  Obstructive apnea/hypopnea index &gt;20/h and a complaint of excessive daytime sleepiness
             before introduction of CPAP therapy

          -  &gt; 15 oxygen desaturations/h (&gt; 3% dips) during an ambulatory nocturnal pulse oximetry
             performed at the end of a 4-night period without CPAP

        Exclusion Criteria:

          -  Sleep disorders other than OSA

          -  More than mild cardiovascular disease, unstable cardiovascular disease

          -  Any lung disease, pulmonary hypertension

          -  Chronic rhinitis

          -  Treatment with drugs that affect respiratory center drive (benzodiazepines or other
             sedatives or sleep inducing drugs, morphine or codeine derivates), stimulants
             (modafinil, methylphenidate, theophylline)

          -  Internal, neurologic or psychiatric disease that interfere with sleep quality

          -  Previous intolerance to moderate or low altitude (&lt; 2600 m)

          -  Exposure to altitudes &gt; 1500m for &gt; 1 day within the last 4 weeks before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Zurich, Pulmonary Division and Sleep Disorders Centre, Zurich, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Zurich, Pulmonary Division and Sleep Disorders Centre</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Latshang TD, Nussbaumer-Ochsner Y, Henn RM, Ulrich S, Lo Cascio CM, Ledergerber B, Kohler M, Bloch KE. Effect of acetazolamide and autoCPAP therapy on breathing disturbances among patients with obstructive sleep apnea syndrome who travel to altitude: a randomized controlled trial. JAMA. 2012 Dec 12;308(22):2390-8. doi: 10.1001/jama.2012.94847.</citation>
    <PMID>23232895</PMID>
  </reference>
  <reference>
    <citation>Latshang TD, Bloch KE, Lynm C, Livingston EH. JAMA patient page. Traveling to high altitude when you have sleep apnea. JAMA. 2012 Dec 12;308(22):2418. doi: 10.1001/jama.2012.4097.</citation>
    <PMID>23232901</PMID>
  </reference>
  <reference>
    <citation>Latshang TD, Bloch KE. How to treat patients with obstructive sleep apnea syndrome during an altitude sojourn. High Alt Med Biol. 2011 Winter;12(4):303-7. doi: 10.1089/ham.2011.1055.</citation>
    <PMID>22206552</PMID>
  </reference>
  <reference>
    <citation>Stadelmann K, Latshang TD, Nussbaumer-Ochsner Y, Tarokh L, Ulrich S, Kohler M, Bloch KE, Achermann P. Impact of acetazolamide and CPAP on cortical activity in obstructive sleep apnea patients. PLoS One. 2014 Apr 7;9(4):e93931. doi: 10.1371/journal.pone.0093931. eCollection 2014.</citation>
    <PMID>24710341</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2009</study_first_posted>
  <last_update_submitted>May 18, 2014</last_update_submitted>
  <last_update_submitted_qc>May 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apnea</keyword>
  <keyword>sleep</keyword>
  <keyword>altitude</keyword>
  <keyword>hypoxia</keyword>
  <keyword>treatment</keyword>
  <keyword>CPAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

